The HIV drug resistance (HIVDR) prevention and assessment strategy, developed by the World Health Organization (WHO) in partnership with HIVResNet, includes monitoring of HIVDR early warning indicators, surveys to assess acquired and transmitted HIVDR, and development of an accredited HIVDR genotyping laboratory network to support survey implementation in resource-limited settings. As of June 2011, 52 countries had implemented at least 1 element of the strategy, and 27 laboratories had been accredited. As access to antiretrovirals expands under the WHO/Joint United Nations Programme on HIV/AIDS Treatment 2.0 initiative, it is essential to strengthen HIVDR surveillance efforts in the face of increasing concern about HIVDR emergence and transmission.

Jordan, M., Bennett, D., Wainberg, M., Havlir, D., Hammer, S., Yang, C., Morris, L., Peeters, M., Wensing, A., Parkin, N., Nachega, J., Phillips, A., De Luca, A., Geng, E., Calmy, A., Raizes, E., Sandstrom, P., Archibald, C., Perriëns, J., Mcclure, C., Hong, S., Mcmahon, J., Dedes, N., Sutherland, D., Bertagnolio, S., Update on World Health Organization HIV drug resistance prevention and assessment strategy: 2004-2011, <<Clinical infectious diseases : an official publication of the Infectious Diseases Society of America>>, 2012; 54 Suppl 4 (Maggio): S245-S245-9. [doi:10.1093/cid/cis206] [http://hdl.handle.net/10807/40454]

Update on World Health Organization HIV drug resistance prevention and assessment strategy: 2004-2011

De Luca, Andrea;
2012

Abstract

The HIV drug resistance (HIVDR) prevention and assessment strategy, developed by the World Health Organization (WHO) in partnership with HIVResNet, includes monitoring of HIVDR early warning indicators, surveys to assess acquired and transmitted HIVDR, and development of an accredited HIVDR genotyping laboratory network to support survey implementation in resource-limited settings. As of June 2011, 52 countries had implemented at least 1 element of the strategy, and 27 laboratories had been accredited. As access to antiretrovirals expands under the WHO/Joint United Nations Programme on HIV/AIDS Treatment 2.0 initiative, it is essential to strengthen HIVDR surveillance efforts in the face of increasing concern about HIVDR emergence and transmission.
2012
Inglese
Jordan, M., Bennett, D., Wainberg, M., Havlir, D., Hammer, S., Yang, C., Morris, L., Peeters, M., Wensing, A., Parkin, N., Nachega, J., Phillips, A., De Luca, A., Geng, E., Calmy, A., Raizes, E., Sandstrom, P., Archibald, C., Perriëns, J., Mcclure, C., Hong, S., Mcmahon, J., Dedes, N., Sutherland, D., Bertagnolio, S., Update on World Health Organization HIV drug resistance prevention and assessment strategy: 2004-2011, <<Clinical infectious diseases : an official publication of the Infectious Diseases Society of America>>, 2012; 54 Suppl 4 (Maggio): S245-S245-9. [doi:10.1093/cid/cis206] [http://hdl.handle.net/10807/40454]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10807/40454
Citazioni
  • ???jsp.display-item.citation.pmc??? 33
  • Scopus 55
  • ???jsp.display-item.citation.isi??? 48
social impact